Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

Cancer of unknown primary site: still an entity, a biological mystery and a metastatic model

Nature Reviews Cancer volume 14, pages 3–4 (2014)Cite this article

Subjects

Abstract

Cancer of unknown primary site (CUP) has frustrated patients, their families and physicians for decades because appropriate therapies for patients with metastatic cancers are determined by the primary site or the tissue of origin. Now that we have methods to identify the tissue of origin for the majority of these patients, additional clinical and biological questions are being asked and addressed.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Greco, F. A. & Hainsworth, J. D. in Cancer: Principles and Practice of Oncology (eds DeVita, V. T. Jr et al.) 9th edn 2033–2051 (Lippincott, Williams and Wilkins, 2011).

    Google Scholar 

  2. Pentheroudakis, G., Golfinopoulos, V. & Pavlidis, N. Switching benchmarks in cancer of unknown primary: from autopsy to microarray. Eur. J. Cancer. 43, 2026–2032 (2007).

    Article  Google Scholar 

  3. Greco, F. A. The impact of molecular testing on treatment of cancer of unknown primary origin. Oncology (Williston Park) 27, 815–817 (2013).

    Google Scholar 

  4. Greco, F. A. Molecular diagnosis of the tissue of origin in cancer of unknown primary site: useful in patient management. Curr. Treat Options Oncol. http://dx.doi.org/10.1007/s11864-013-0257-1 (2013).

  5. Greco, F. A. et al. Molecular profiling diagnosis in unknown primary cancer: accuracy and ability to complement standard pathology. J. Natl Cancer Inst. 105, 782–790 (2013).

    Article  CAS  Google Scholar 

  6. Schwartz, A. M. & Harpaz, N. J. A primary approach to cancers of unknown primary. J. Natl Cancer Inst. 105, 759–761 (2013).

    Article  Google Scholar 

  7. Hainsworth, J. D. et al. Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon Research Institute. J. Clin. Oncol. 31, 217–223 (2013).

    Article  CAS  Google Scholar 

  8. DePalma, M. & Hanahan, D. The biology of personalized cancer medicine: facing individual complexities underlying hallmark capabilities. Mol. Oncol. 6, 111–127 (2012).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Sarah Cannon Cancer Center, Sarah Cannon Research Institute, Tennessee Oncology, Nashville, 37203, Tennessee, USA

    F. Anthony Greco

Authors
  1. F. Anthony Greco
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to F. Anthony Greco.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Greco, F. Cancer of unknown primary site: still an entity, a biological mystery and a metastatic model. Nat Rev Cancer 14, 3–4 (2014). https://doi.org/10.1038/nrc3646

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrc3646

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer